Hikma Enjoys Luxury Of M&A Opportunism
No Pressure To Deliver Major Transaction, But In A Position To Do So
Executive Summary
Hikma CEO Siggi Olafsson says the firm is in a position to execute a major deal if the right opportunity comes along, but is not under any pressure to pursue M&A for its own sake.
You may also be interested in...
Hikma Buys Injectables Specialist Custopharm In $400m+ Deal
Hikma has agreed to acquire US sterile injectables specialist Custopharm in a deal that includes a $375m upfront purchase price and a further $50m in milestone payments. The transaction is set to bolster Hikma’s near-$1bn injectables business that currently accounts for around two-fifths of turnover.
Hikma Opens Discussions To Acquire GSK OTC, Rx Businesses In Egypt, Tunisia
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.
Hikma Opens Discussions To Acquire GSK Businesses In Egypt And Tunisia
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.